Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2013 17:00 ET | Source: Gentium S.p.A.

Gentium Receives Positive Opinion From EMA's COMP for Defibrotide for the Prevention of GvHD

VILLA GUARDIA, Italy, Oct. 10, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Medicines Agency's Committee for Orphan Medicinal Products...
October 02, 2013 06:00 ET | Source: Gentium S.p.A.

Salvatore Calabrese Appointed to Chief Operating Officer at Gentium S.p.A.

VILLA GUARDIA (COMO), Italy, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has promoted Salvatore Calabrese to the position of Chief Operating...
August 13, 2013 06:00 ET | Source: Gentium S.p.A.

Gentium Reports First Half 2013 Financial Results

Positive Opinion from EMA's CHMP for Defitelio®. Defibrotide revenues up 26% to EUR 14.26 million (USD 18.55 million) for the six-month period ended June 30, 2013 from EUR 11.35 million...
August 01, 2013 07:00 ET | Source: Gentium S.p.A.

Gentium to Report First Half 2013 Financial Results

VILLA GUARDIA (COMO), Italy, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it will report its financial results for the first half of 2013 on...
July 26, 2013 07:40 ET | Source: Gentium S.p.A.

Gentium Receives Positive Opinion From EMA's CHMP for Defitelio

VILLA GUARDIA, Italy, July 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that, following its request for re-examination, the European Medicines Agency's...
July 26, 2013 07:16 ET | Source: Gentium S.p.A.

Gentium Provides EMA Update

VILLA GUARDIA (COMO), Italy, July 26, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced that today, Friday, July 26, 2013, it will provide update on Defibrotide Marketing...
June 04, 2013 06:00 ET | Source: Gentium S.p.A.

Gentium Provides Update on Re-Examination of Defibrotide MAA to EMA

VILLA GUARDIA, Italy, June 4, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that, the Company has filed the documentation requesting a Re-examination of the...
May 14, 2013 07:00 ET | Source: Gentium S.p.A.

Gentium Reports First Quarter Financial Results

Defibrotide usage increased by 32% to EUR 6.49 million (US$ 8.31 million). Product sales of EUR 7.54 million (US$ 9.65 million) for the three month period ended March 31, 2013, recording an...
April 16, 2013 06:30 ET | Source: Gentium S.p.A.

Gentium to Request Re-Examination of CHMP Opinion on Defibrotide

VILLA GUARDIA, Italy, April 16, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that it has requested a re-examination of the negative opinion adopted, by the...
April 09, 2013 16:30 ET | Source: Gentium S.p.A.

Satellite Symposia on Defibrotide and Veno-Occlusive Disease at EBMT 39th Annual Meeting

VILLA GUARDIA (COMO), Italy, April 9, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the Company's lead product, Defibrotide, was the subject of two...